ACADIA Pharmaceuticals Inc.ACADNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank29
3Y CAGR-45.1%
5Y CAGR-23.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-45.1%/yr
vs +19.0%/yr prior
5Y CAGR
-23.8%/yr
Recent deceleration
Acceleration
-64.1pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 8.43% |
| 2024 | -13.76% |
| 2023 | -2.75% |
| 2022 | 51.02% |
| 2021 | -24.98% |
| 2020 | 32.76% |
| 2019 | 28.44% |
| 2018 | 25.45% |
| 2017 | 50.26% |
| 2016 | 34.41% |